

## Bipolar Disorder Working Group meeting

**Date:** 6/02/2023

**Location:** Virtual

**Minutes:** Confirmed

<b>Committee members present:</b>		
Elizabeth Kay (Chair)		Present for notes 1 – 3
Priya Natarajan		Present for notes 1 – 3
Zoe Pease		Present for notes 1 – 3
Ivan Kennes		Present for notes 1 – 3
Nigel Barnes		Present for notes 1 – 3
Claire Coppens		Present for notes 1 – 3
<b>Apologies:</b>		
Aditya Sharma		

<b>In attendance:</b>		
Angela Bennett	Director of Guidelines, GDT-NGA	Present for notes 1 – 3
Hilary Eadon	Guideline Lead, GDT- NGA	Present for notes 1 - 3
Eric Power	Programme Director	Present for notes 1 – 3
Steve Pilling	Clinical Adviser, GDT- NGA	Present for notes 1 – 3
Odette Megnin-Viggars	Senior Systematic Reviewer, GDT-NGA	Present for notes 1 – 3
Catharine Baden-Daintree	Senior Medical Editor	Present for notes 1 – 3
Sarah Mee	Senior Medical Assessor, MHRA	Present for notes 1 – 3
Leigh Henderson	Head of Neuropsychiatric disorders, Cognition and Mental Health Safety and Surveillance, MHRA	Present for notes 1 – 3

### **1. Welcome and objectives for the meeting**

The Chair welcomed the members and attendees to the 1st meeting of the Bipolar Disorder Working Group.

The Chair informed the Working Group that apologies had been received from Aditya Sharma.

The Chair outlined the objectives of the meeting, which were to review the recommendations from GC185 about the use of sodium valproate and agree if changes were needed in light of changes made to the regulations by the MHRA.

### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was use of sodium valproate for the treatment of bipolar disorder

A record of the interests declared by Working Group members is available on the NICE website. No new interests were declared at the meeting.

A senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Presentations and discussion**

The Chair introduced Sarah Mee, Senior Medical Assessor, MHRA, who gave a presentation on the 2022 CHM review of valproate.

The Chair introduced Odette Megnin-Viggars, Senior Systematic Reviewer, GDT-NGA who presented the effectiveness data for valproate in the treatment of acute mania and long-term management, published since CG185.

The Working Group then discussed the issues presented in relation to the treatment of acute mania.

**Date of next meeting:** 13/2/23

**Location of next meeting:** Virtual